2 Information about olaparib

Marketing authorisation indication

2.1 Olaparib (Lynparza, AstraZeneca) is indicated 'as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for olaparib.


2.3 The price for olaparib is £2,317.50 per pack of 56 tablets, each containing 100 mg or 150 mg of the active ingredient (excluding VAT; BNF online, March 2023). The company has a commercial arrangement. This makes olaparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.